Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
On July 15, 2009, administrators notified the company of an increase in share interests for specific individuals following the re-investment of dividends paid on July 9, 2009. The transaction price was £10.91 per share. The specific increases were:
- Mr E J Gray: 297.32 shares
- Mr S A Hussain: 532.93 shares
- Mr D S Redfern: 235.21 shares
- Ms C Thomas: 147.01 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the dividend re-investment price of £10.91 per share against market data for July 9, 2009.
- Confirm the total shareholding positions of the named directors post-transaction.
- Review the full Deferred Investment Award Plan rules to understand the mechanics of the dividend re-investment.